Drug maker TaiGen Biotechnology Co (太景生技) is expected to launch its first product across the Taiwan Strait in the next two years.
One of the company’s products, Nemonoxacin, which goes by the trade name Taigexyn and was developed as a treatment for pneumonia and skin infections, is expected to receive a drug permit for an oral formulation in the first half of next year from both the Taiwanese and Chinese food and drug administrations, TaiGen chairman and chief executive officer Hsu Ming-chu (許明珠) said at an investors’ conference on Thursday.
The oral antibiotic drug is likely to hit the Chinese market in the second half of next year and the Taiwanese market in the first half of 2015, Hsu added.
TaiGen last year licensed China-based Zhejiang Medicine Co (浙江醫藥集團) to make and sell Nemonoxacin in China.
TaiGen is expected to receive between US$1 million and US$5 million of milestone payments from Zhejiang Medicine, as well as royalties of 7 percent to 11 percent on future sales of the drug in China, the company said.
Citing the sales of two similar drugs in China, Hsu estimated that Nemonoxacin’s market value in China would be 1 billion yuan (US$165 million) a year.
The company is seeking to license Nemonoxacin to companies, with the intention of them filing third-phase clinical trials in Europe and the US and then selling the drug in those places, Hsu said.
TaiGen is also looking for partners to file second-phase clinical trials of cocktail treatments for hepatitis C using TG-2349, Hsu said.
“TG-2349 is used to inhibit protease in the hepatitis C virus, and we are looking for companies with polymerase inhibitor or inhibitors for nonstructural protein 5A,” Hsu said. “However, because we plan to enter China with the drug ourselves, we are seeking partners without operations in China.”
Lotus Pharmaceutical Co (美時化學製藥), which makes and distributes oral and injection medicines, will manufacture TaiGen’s Nemonoxacin on a contract basis for markets other than China, Europe and the US.
TaiGen said it plans to develop its own manufacturing capacity in China in the next two to three years.
“We will purchase a formulation factory in China as soon as we have enough money, because the Chinese government demands that we make drugs locally,” she said.
Nemonoxacin is the first drug from Taiwan to meet the requirements to be registered as a category 1.1 new drug in China, which will enable it to reap a higher price premium, the company said.
STOCK MARKET LISTING
Meanwhile, TaiGen plans to raise up to NT$1.1 billion (US$36.6 million) ahead of its TAIEX listing on Jan. 17, as the company will issue 22 million new shares at about NT$50 each, with 10 percent of the new shares to be reserved for its employees.
The company plans to use the proceeds as working capital for new drug development and to repay bank loans.
In the January to September period, the company posted losses of NT$271.86 million, or NT$0.42 per share.
HEAVY INVESTMENT: Moody’s affirmed the firm’s ‘Aa3’ rating with a ‘stable’ outlook due to its leading position in the industry and ability to match customer requirements Taiwan Semiconductor Manufacturing Co’s (TSMC, 台積電) revenue this year is expected to increase about 21 percent to NT$1.29 trillion (US$44.01 billion) from NT$1.07 trillion last year, driven by strong demand for advanced 5-nanometer and 7-nanometer chips mainly used in smartphones and high-performance computing devices, a Moody’s Investors Service report on Wednesday said. TSMC’s rate of revenue growth next year is to increase to 7.5 percent, the ratings agency said. The company, which supplies 5-nanometer chips for Apple Inc’s new iPad series, has introduced the advanced chips ahead of its competitors and gained a significant share of the market for the foundry industry’s
NO VIRUS BLUES: A SEMI Taiwan official said that the virus does not slow down the global semiconductor industry’s investment in manufacturing equipment The production value of the nation’s semiconductor industry is expected to grow 16.7 percent this year from last year, outpacing the global industry’s 3.3 percent growth, industry association SEMI said yesterday. That would help Taiwan safeguard its second spot in the global semiconductor market with a production value of more than NT$3 trillion (US$102.73 billion), SEMI Taiwan president Terry Tsao (曹世綸) told a media briefing in Taipei for the Semicon Taiwan trade show beginning today. The global semiconductor industry’s production value is expected to increase to US$426 billion this year, SEMI said. In terms of semiconductor equipment investment, equipment billings from Taiwanese firms
Taipei Times: When do you think the hospitality industry can return to how it was before the COVID-19 pandemic? How does Formosa International Hotels Group (FIH, 晶華酒店集團) fare this quarter and beyond? FIH chairman Steve Pan (潘思亮): The virus outbreak will have a serious impact on business travel, driven mainly by meetings, incentive travel, conferences and exhibitions over the past three decades. For the past six months, many businesspeople have grown used to exchanging information on the Internet, where more people can participate. The trend might sustain for three to five years until people are vaccinated and it is safe to
DIGITAL COMMERCE: In 2016, only 2 percent of orders were delivered in Taiwan, but that has risen to 10 percent, Foodpanda Taiwan Co operations director Nick Yu said Online food delivery platforms have seen explosive growth in Taiwan this year, helped by business opportunities related to the COVID-19 pandemic, company executives said at a digital commerce conference in Taipei yesterday. When the threat of COVID-19 kept people from going out to eat, more people experimented with ordering food deliveries online, Foodpanda Taiwan Co Ltd (富胖達) operations director Nick Yu (余岳勳) said. Foodpanda started operations in Taiwan in 2012. “We experienced 5,000 percent growth in the past 24 months,” Yu said. “That’s more than the previous six years combined.” In 2016, only 2 percent of food orders were delivered in Taiwan, but that